Petrichor Healthcare Capital Management

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Evergreen Theragnostics, Inc. is a contract development and manufacturing organization based in Jersey City, New Jersey, specializing in radiopharmaceuticals. Established in 2019, the company offers a comprehensive range of services including manufacturing, technology transfer, method validation, regulatory support, logistics, and distribution. Evergreen Theragnostics focuses on improving treatment options for cancer patients by providing reliable services for both therapeutic and diagnostic radiopharmaceuticals, guiding clients through all stages from early development to commercialization. With a highly skilled team experienced in the intricacies of radiopharmaceutical commercialization and regulatory affairs, Evergreen Theragnostics positions itself as a valuable partner in the growing field of theragnostics.

Avalo Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing highly targeted therapeutics for immune dysregulation and other areas of significant unmet clinical need. The company employs a precision medicine approach in its research and development efforts. Its lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody designed to address inflammatory diseases. In addition to AVTX-009, Avalo's pipeline includes quisovalimab, an anti-LIGHT monoclonal antibody, and AVTX-008, a BTLA agonist fusion protein, which further exemplify its commitment to advancing innovative treatments for complex medical conditions.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on developing treatments for cancer. Its lead product, PEDMARK, is a formulation of Sodium Thiosulfate designed to prevent cisplatin-induced hearing loss, or ototoxicity, in children undergoing chemotherapy. PEDMARK has completed Phase III clinical trials and is being evaluated in two pediatric studies to assess its effectiveness in reducing hearing loss and its potential impact on survival. Founded in 1996 and formerly known as Adherex Technologies Inc., Fennec Pharmaceuticals aims to address the significant challenges faced by children receiving chemotherapy, particularly the added burden of hearing loss during an already difficult time.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

VERO Biotech LLC is a development stage biopharmaceutical company based in Atlanta, Georgia, focused on creating innovative solutions for patients with pulmonary and cardiac diseases. The company specializes in the design, development, and commercialization of inhaled nitric oxide (NO) products, utilizing its GeNOsyl drug delivery technology. This technology comprises a single-use drug cassette paired with either a portable console or a wearable controller, facilitating the safe delivery of NO for various therapeutic applications. VERO Biotech is developing GeNOsyl Acute DS for acute vasoreactivity testing in patients with pulmonary arterial hypertension (PAH) and for treating pulmonary hypertension in post-surgical patients and newborns with hypoxic respiratory failure. Additionally, it is working on GeNOsyl Chronic DS for managing PAH and pulmonary hypertension associated with idiopathic pulmonary fibrosis. By providing user-friendly and portable NO delivery systems, VERO Biotech aims to improve clinical workflows and address the unmet medical needs in these patient populations.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on developing treatments for cancer. Its lead product, PEDMARK, is a formulation of Sodium Thiosulfate designed to prevent cisplatin-induced hearing loss, or ototoxicity, in children undergoing chemotherapy. PEDMARK has completed Phase III clinical trials and is being evaluated in two pediatric studies to assess its effectiveness in reducing hearing loss and its potential impact on survival. Founded in 1996 and formerly known as Adherex Technologies Inc., Fennec Pharmaceuticals aims to address the significant challenges faced by children receiving chemotherapy, particularly the added burden of hearing loss during an already difficult time.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on developing treatments for cancer. Its lead product, PEDMARK, is a formulation of Sodium Thiosulfate designed to prevent cisplatin-induced hearing loss, or ototoxicity, in children undergoing chemotherapy. PEDMARK has completed Phase III clinical trials and is being evaluated in two pediatric studies to assess its effectiveness in reducing hearing loss and its potential impact on survival. Founded in 1996 and formerly known as Adherex Technologies Inc., Fennec Pharmaceuticals aims to address the significant challenges faced by children receiving chemotherapy, particularly the added burden of hearing loss during an already difficult time.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on developing treatments for cancer. Its lead product, PEDMARK, is a formulation of Sodium Thiosulfate designed to prevent cisplatin-induced hearing loss, or ototoxicity, in children undergoing chemotherapy. PEDMARK has completed Phase III clinical trials and is being evaluated in two pediatric studies to assess its effectiveness in reducing hearing loss and its potential impact on survival. Founded in 1996 and formerly known as Adherex Technologies Inc., Fennec Pharmaceuticals aims to address the significant challenges faced by children receiving chemotherapy, particularly the added burden of hearing loss during an already difficult time.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development, specifically aimed at reducing systemic inflammation in patients undergoing cardiac surgery. The company specializes in protein stabilizing technologies that leverage bioinformatics and artificial intelligence to enhance the formulation of biopharmaceuticals, viral vectors, and vaccines. Additionally, Leukocare develops biofunctionalized devices designed to minimize leukocyte activity in extracorporeal blood circuits using targeted antibodies. By integrating advanced formulation techniques with cutting-edge technology, Leukocare aims to improve patient outcomes and ensure safer surgical procedures.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development, specifically aimed at reducing systemic inflammation in patients undergoing cardiac surgery. The company specializes in protein stabilizing technologies that leverage bioinformatics and artificial intelligence to enhance the formulation of biopharmaceuticals, viral vectors, and vaccines. Additionally, Leukocare develops biofunctionalized devices designed to minimize leukocyte activity in extracorporeal blood circuits using targeted antibodies. By integrating advanced formulation techniques with cutting-edge technology, Leukocare aims to improve patient outcomes and ensure safer surgical procedures.

ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

Persivia Inc. is a healthcare IT company based in Marlborough, Massachusetts, that specializes in providing an AI-driven platform for managing value-based care programs. Established in 2005, the company offers a population health management solution designed for hospitals, payers, and healthcare providers. Persivia's platform integrates clinical, socioeconomic, and claims data to create a comprehensive view of patient care, enabling personalized treatment and improved health outcomes. The platform supports various functionalities, including chronic care management, quality reporting, care coordination, and clinical analytics, facilitating compliance with government regulations and enhancing the management of population risk. Through its innovative technology, Persivia aims to improve care quality while reducing costs for healthcare organizations.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.